ir.avenuetx.comAvenue Therapeutics, Inc. (ATXI)
ir.avenuetx.com Profile
Ir.avenuetx.com is a subdomain of Avenuetx.com, which was created on 2015-06-09,making it 9 years ago.
Description：Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is...
Discover ir.avenuetx.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.avenuetx.com Information
| HomePage size: 55.482 KB |
| Page Load Time: 0.811295 Seconds |
| Website IP Address: 3.114.49.24 |
ir.avenuetx.com Similar Website
| Aratana Therapeutics Investor Overview |
| Jobs at Spark Therapeutics |
| Viridian Therapeutics, Inc. - Investors & Media |
| Clinical Pharmacology and Therapeutics Jobs - American Society for Clinical Pharmacology and Therape |
| Homepage | Drug and Therapeutics Bulletin |
| Investor Relations :: Checkpoint Therapeutics, Inc. (CKPT) |
| Investor Relations | TG Therapeutics, Inc. |
| Revance Therapeutics, Inc. - Investor Relations |
| Investors | PTC Therapeutics, Inc. |
| Acorda Therapeutics Inc - Investors |
| Investor Relations :: BioXcel Therapeutics, Inc. (BTAI) |
| Investors | Flexion Therapeutics, Inc. |
| Mirati Therapeutics Inc. - Investor & Media Relations |
| Edgewise Therapeutics, Inc. - Investor |
| Halozyme Therapeutics, Inc. - Investor |
ir.avenuetx.com PopUrls
| Avenue Therapeutics, Inc. (ATXI) https://ir.avenuetx.com/ |
| Financial Results :: Avenue Therapeutics, Inc. (ATXI) https://ir.avenuetx.com/financial-information/financial-results |
| Press Releases :: Avenue Therapeutics, Inc. (ATXI) https://ir.avenuetx.com/news-events/press-releases |
| News & Events :: Avenue Therapeutics, Inc. (ATXI) https://ir.avenuetx.com/news-events |
| Financial Information :: Avenue Therapeutics, Inc. (ATXI) https://ir.avenuetx.com/financial-information |
| Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent ... https://ir.avenuetx.com/news-events/press-releases/detail/67/avenue-therapeutics-reports-full-year-2022-financial |
| Avenue Therapeutics Receives Complete Response Letter from the FDA for ... https://ir.avenuetx.com/news-events/press-releases/detail/10/avenue-therapeutics-receives-complete-response-letter-from |
| Avenue Therapeutics Reports Third Quarter 2023 Financial Results and ... https://ir.avenuetx.com/news-events/press-releases/detail/78/avenue-therapeutics-reports-third-quarter-2023-financial |
| Avenue Therapeutics Reports Second Quarter 2023 Financial Results and ... https://ir.avenuetx.com/news-events/press-releases/detail/74/avenue-therapeutics-reports-second-quarter-2023-financial |
| SEC Filings :: Avenue Therapeutics, Inc. (ATXI) https://ir.avenuetx.com/sec-filings |
ir.avenuetx.com Httpheader
| Date: Sun, 12 May 2024 01:00:17 GMT |
| Server: Apache |
| X-Frame-Options: SAMEORIGIN |
| Strict-Transport-Security: max-age=31536000; |
| X-XSS-Protection: 1; mode=block |
| X-Content-Type-Options: nosniff |
| Feature-Policy: "microphone none; camera none; geolocation none; screen-wake-lock none;", Referrer-Policy: strict-origin-when-cross-origin |
| Vary: Accept-Encoding |
| Transfer-Encoding: chunked |
| Content-Type: text/html; charset=UTF-8 |
ir.avenuetx.com Meta Info
| content="ie=edge" http-equiv="x-ua-compatible"/ |
| charset="utf-8"/ |
| content="width=device-width, initial-scale=1, maximum-scale=1" name="viewport"/ |
| content="https://ir.avenuetx.com" property="og:url"/ |
| content="Avenue Therapeutics, Inc." property="og:site_name"/ |
| content="Investors" property="og:title"/ |
| content="website" property="og:type"/ |
| content="https://d1io3yog0oux5.cloudfront.net/_8f5f34c81e69bff57b45728d6a8819ad/avenuetx/db/2233/20222/social_image_resized.jpg" property="og:image"/ |
| content="summary_large_image" name="twitter:card"/ |
| content="Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is currently developing three assets including AJ201,…" property="og:description"/ |
| content="Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is currently developing three assets including AJ201,…" name="description"/ |
| content="#ffffff" name="theme-color"/ |
ir.avenuetx.com Ip Information
| Ip Country: Japan |
| City Name: Tokyo |
| Latitude: 35.6893 |
| Longitude: 139.6899 |
ir.avenuetx.com Html To Plain Text
Management Team Board of Directors Pipeline AJ201 BAER-101 IV Tramadol Publications Investors News & Events Overview Press Releases IR Calendar Email Alerts Company Info Overview Management Team Presentations Contacts FAQ Financial Info Overview Financial Results Income Statement Balance Sheet Cash Flow Analyst Coverage Stock Data Quote Charts Historical Data SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Events Contact Us Careers Email Alerts Company Overview Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator for CNS diseases, and IV Tramadol, which is in Phase 3 clinical development for the management of moderate-to-moderately-severe pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com . Investors Investors News & Events Overview Press Releases IR Calendar Email Alerts Company Info Overview Management Team Presentations Contacts FAQ Financial Info Overview Financial Results Income Statement Balance Sheet Cash Flow Analyst Coverage Stock Data Quote Charts Historical Data SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Latest News View All News Apr 29, 2024 Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds Read Press Release Apr 24, 2024 Avenue Therapeutics Announces Reverse Stock Split Mar 25, 2024 Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 Mar 18, 2024 Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights View All News Latest Presentation May 1, 2024 Investor Presentation View Presentation Upcoming Event Jun 24, 2024 9:30 am EDT Annual Meeting of Stockholders View Event Add to Calendar View All Events Latest Financial Results FY 2023 Fiscal Year Ended Dec 31, 2023 Earnings Release PDF HTML 10-K Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Filing For Fiscal Year Ending Dec 31, 2023 Report Links Annual Report Document Links View 10-K Email Alerts Sign up today and receive company updates straight to your inbox. Sign up today Company Overview Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator for CNS diseases, and IV Tramadol, which is in Phase 3 clinical development for the management of moderate-to-moderately-severe pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com . View Management Team View Board of Directors Stock Information IR Contacts Headquarters Avenue Therapeutics, Inc. 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154 Investor Relations Jaclyn Jaffe T: 781-652-4500 ir@avenuetx.com Transfer Agent VStock Transfer, LLC 18 Lafayette Place Woodmere, NY 11598 T: 212-828-8436 info@vstocktransfer.com https://www.vstocktransfer.com Email Alerts Contacts RSS News Feed Privacy Disclaimer Contact Us Website Design, Maintenance and Hosting by Tidal Media Group Copyright ©2024 Avenue Therapeutics . Market Data copyright © 2024 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT =Real-Time, EOD =End of Day, PD =Previous Day. Market Data powered by QuoteMedia . Terms of Use...
ir.avenuetx.com Whois
Domain Name: AVENUETX.COM Registry Domain ID: 1937189714_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2024-04-10T06:38:26Z Creation Date: 2015-06-09T20:39:58Z Registry Expiry Date: 2027-06-09T20:39:58Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: domain.operations@web.com Registrar Abuse Contact Phone: +1.8777228662 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS55.WORLDNIC.COM Name Server: NS56.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T14:31:31Z <<<